Close Menu

NEW YORK – Enzo Biochem reported after the close of the market on Monday that revenues for its fiscal third quarter fell 14 percent year over year, as the COVID-19 pandemic adversely affected its clinical services revenues, diagnostic testing volumes, and product revenues.

For the three months ended April 30, the diagnostics company reported total revenues of $16.9 million compared to $19.7 million in the year-ago quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.